Comparisons of the clinicopathological features and survival outcomes between lung cancer patients with adenocarcinoma and squamous cell carcinoma.

Item

http://www.wikidata.org/entity/Q40891431

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Comparisons of the clinicopath ...... a and squamous cell carcinoma.

@en

type

Item

label

Comparisons of the clinicopath ...... a and squamous cell carcinoma.

@en

prefLabel

Comparisons of the clinicopath ...... a and squamous cell carcinoma.

@en

P1476

Comparisons of the clinicopath ...... ma and squamous cell carcinoma

@en

P2093

Kohei Yokoi

http://www.w3.org/2001/XMLSchema#string

Koichi Fukumoto

http://www.w3.org/2001/XMLSchema#string

Shota Nakamura

http://www.w3.org/2001/XMLSchema#string

Takayuki Fukui

http://www.w3.org/2001/XMLSchema#string

Tetsuo Taniguchi

http://www.w3.org/2001/XMLSchema#string

Yukinori Sakao

http://www.w3.org/2001/XMLSchema#string

P2860

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals.

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.

Controversy about small peripheral lung adenocarcinomas: how should we manage them?

Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer.

The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours

P2888

s11748-015-0564-5

P304

507-513

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11748-015-0564-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Koji Kawaguchi

P577

2015-05-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26022944

http://www.w3.org/2001/XMLSchema#string

P921

adenocarcinoma